Metabasis Therapeutics Announces Publication of Its Novel Computer-Aided Drug Design Technology for Drug Discovery in the Journal of the American Chemical SocietySAN DIEGO--(BUSINESS WIRE)--Sep 4, 2007 - Metabasis Therapeutics, Inc. (Nasdaq:MBRX), a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of metabolic and liver diseases by targeting the liver and liver pathways, announced today that an article entitled "Relative Binding Affinities of Fructose-1,6-Bisphosphatase Inhibitors Calculated Using a Quantum Mechanics-Based Free Energy Perturbation Method" by M. Rami Reddy and Mark Erion, was published in the Journal of the American Chemical Society (JACS), Vol. 129, Issue No. 30, pp. 9296-9297, (2007).
The publication describes the integration of Quantum Mechanics (QM) into a method known as free energy perturbation (FEP) and the use of the resulting QM/molecular mechanics (MM)-based FEP method for drug design. The communication also included a novel computer-aided drug design strategy for achieving accurate predictions that has been used by Metabasis to calculate the relative inhibitory potencies of several structurally-diverse fructose-1,6-bisphosphatase (FBPase) inhibitors. This method has been used by Metabasis in its drug discovery programs focused on the use of these inhibitors for the treatment of type 2 diabetes. The results were shown to be consistent with experimental data thereby demonstrating both the accuracy of the method and its potential in drug design.
"The publication of this communication in JACS reflects the potential value of the QM/MM-based FEP approach in drug discovery," stated Dr. Mark Erion, Metabasis' executive vice president of research and development and chief scientific officer. "The use of this method can provide important insights into the binding interactions of drug candidates and thereby enable better selection of candidate compounds to be synthesized and tested. In addition, unlike conventional FEP approaches, the QM/MM-based method is capable of automation and code parallelization which will increase throughput and ultimately significantly reduce the time and cost to discover potential drug candidates."
For the past 4 years, Dr. Reddy, senior director of computational chemistry, structural biology and cheminformatics and Dr. Mark Erion, in consultation with Dr. U. Chandra Singh, president and chief scientific officer of AM Technology, have been developing this computational strategy. The calculations reported in the manuscript were conducted on IBM System P570 and P650 multi-processor servers.
"Metabasis is applying the same computer-aided design technology used by engineers and industrial designers to automate key parts of the drug-discovery process," said David Turek, vice president of deep computing at IBM. "The CADD technology running on Metabasis' IBM System supercomputer significantly reduces the time required for drug-simulation processes by eliminating the need to synthesize and test many of the compounds that would normally be a part of the drug-discovery process."
"Metabasis' proprietary technology and know-how, including our expertise with computer-aided drug design, has enabled our discovery team to move five product candidates into clinical development since the Company's inception," said Dr. Paul Laikind, Metabasis' president and chief executive officer. "This excellent productivity is continuing with several more metabolic disease candidates discovered by our team approaching a recommendation for further development."
About Metabasis (www.mbasis.com):
Metabasis Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs to address some of the world's most widespread and costly chronic diseases. The Company has established a pipeline that includes clinical stage and preclinical product candidates targeting major diseases with significant unmet medical needs. Targeted diseases include metabolic diseases such as diabetes, hyperlipidemia and obesity as well as liver diseases such as hepatitis and primary liver cancer. Metabasis has developed several proprietary technologies for use in discovering and optimizing drugs, including the NuMimetic(TM) and HepDirect(R) technologies. Metabasis is continuing to identify and develop new product candidates using its proprietary technologies and expertise.
Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, reference to the capabilities and potential value of the QM/MM-based FEP approach. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause Metabasis' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, the progress and timing of clinical trials for Metabasis' product candidates; the fact that positive results from clinical trials does not necessarily mean later clinical trials will succeed; serious adverse side effects of, or serious adverse events related to, Metabasis' product candidates or proprietary technologies; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing Metabasis' product candidates; the potential and progress of preclinical compounds and programs; and other factors discussed in the "Risk Factors" section of Metabasis' Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. All forward-looking statements are qualified in their entirety by this cautionary statement. Metabasis is providing this information as of this date of this release and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
Metabasis Therapeutics, Inc.
Constance Bienfait, Vice President
Investor Relations & Corporate Communications
Posted: September 2007